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BACKGROUND
Respiratory syncytial virus (RSV) is the dominant cause of severe lower respiratory 
tract infection in infants, with the most severe cases concentrated among younger 
infants.
METHODS
Healthy pregnant women, at 28 weeks 0 days through 36 weeks 0 days of gesta-
tion, with an expected delivery date near the start of the RSV season, were ran-
domly assigned in an overall ratio of approximately 2:1 to receive a single intra-
muscular dose of RSV fusion (F) protein nanoparticle vaccine or placebo. Infants 
were followed for 180 days to assess outcomes related to lower respiratory tract 
infection and for 364 days to assess safety. The primary end point was RSV-asso-
ciated, medically significant lower respiratory tract infection up to 90 days of life, 
and the primary analysis of vaccine efficacy against the primary end point was 
performed in the per-protocol population of infants (prespecified criterion for suc-
cess, lower bound of the 97.52% confidence interval [CI] of ≥30%).
RESULTS
A total of 4636 women underwent randomization, and there were 4579 live births. 
During the first 90 days of life, the percentage of infants with RSV-associated, 
medically significant lower respiratory tract infection was 1.5% in the vaccine group 
and 2.4% in the placebo group (vaccine efficacy, 39.4%; 97.52% CI, −1.0 to 63.7; 95% 
CI, 5.3 to 61.2). The corresponding percentages for RSV-associated lower respiratory 
tract infection with severe hypoxemia were 0.5% and 1.0% (vaccine efficacy, 48.3%; 
95% CI, −8.2 to 75.3), and the percentages for hospitalization for RSV-associated 
lower respiratory tract infection were 2.1% and 3.7% (vaccine efficacy, 44.4%; 95% 
CI, 19.6 to 61.5). Local injection-site reactions among the women were more com-
mon with vaccine than with placebo (40.7% vs. 9.9%), but the percentages of par-
ticipants who had other adverse events were similar in the two groups.
CONCLUSIONS
RSV F protein nanoparticle vaccination in pregnant women did not meet the pre-
specified success criterion for efficacy against RSV-associated, medically significant 
lower respiratory tract infection in infants up to 90 days of life. The suggestion of a 
possible benefit with respect to other end-point events involving RSV-associated re-
spiratory disease in infants warrants further study. (Funded by Novavax and the Bill 
and Melinda Gates Foundation; ClinicalTrials.gov NCT02624947.)
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RSV Vaccination during Pregnancy
Respiratory syncytial virus (RSV) is the dominant cause of hospitalizations in infants with lower respiratory tract infec-
tions. In 2015, an estimated 3.2 million hospi-
talizations for RSV-associated lower respiratory 
tract infection occurred in children younger than 
5 years of age worldwide; 118,000 of the hospi-
talized children died. Approximately 44% of 
those hospitalizations and 46% of the in-hospital 
deaths occurred in infants younger than 6 months 
of age.1 No licensed RSV vaccine exists, and 
timely, active immunization against RSV infec-
tion in the first 3 to 6 months of life may be 
challenging. Passive immunity through transfer 
of IgG antibodies from immunized pregnant 
women offers an alternative and is endorsed by 
the World Health Organization (WHO) for the 
prevention of tetanus, influenza, and pertussis 
in infants.2-4 Passive immunity conferred by 
palivizumab, a monoclonal antibody to RSV fu-
sion (F) protein, reduced the risk of hospitaliza-
tion for RSV-associated lower respiratory tract 
infection among premature infants and among 
infants with chronic lung disease or congeni-
tal heart disease,5 and motavizumab (a higher-
potency monoclonal antibody) reduced the risk 
of hospitalization for RSV-associated lower respi-
ratory tract infection by 87% among American 
Indian infants born at term.6
In a previous trial, recombinant RSV F pro-
tein nanoparticle vaccine (RSV F vaccine) had an 
acceptable safety profile when administered in 
pregnant women and elicited RSV A and B neu-
tralizing antibodies, antibodies to RSV F protein 
site II epitope (palivizumab-competitive anti-
bodies), and antibodies to other epitopes with 
broadly neutralizing activity. These antibodies 
were efficiently transferred to the infants.7 Here, 
we describe the results of a phase 3 trial evaluat-
ing the safety and immunogenicity of RSV F vac-
cine in pregnant women and vaccine efficacy 
against RSV-associated lower respiratory tract 
infection in their infants through the first 90 
and 180 days of life.
Me thods
Trial Design and Oversight
A randomized, observer-blind, placebo-controlled 
trial was performed at 87 sites in Argentina, 
Australia, Chile, Bangladesh, Mexico, New Zea-
land, the Philippines, South Africa, Spain, the 
United Kingdom, and the United States. Healthy 
women 18 to 40 years of age with low-risk sin-
gleton pregnancies received vaccine or placebo 
between 28 weeks 0 days and 36 weeks 0 days of 
gestation, before the seasonal circulation of RSV 
in their locale (see Section S1.1 in the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org). Inclusion and exclu-
sion criteria are provided in Section S1.2 and the 
randomization scheme in Section S1.3. The full 
protocol with the statistical analysis plan is also 
available at NEJM.org.
The trial staff conducted weekly active sur-
veillance of parents or caregivers until 180 days 
after delivery (see Section S1.4) for the detection 
of symptoms of lower respiratory tract infection. 
Evaluations could also be triggered by spontane-
ous reports from the parent or caregiver. The 
evaluation of infants included physical examina-
tion, determination of respiratory rate, and pulse 
oximetry with the use of a RAD-5 pulse oximeter 
(Masimo) provided by the sponsor (Novavax). 
Nasal swab samples were obtained with the use 
of a nasal FLOQSwab (Copan Diagnostics) and 
were placed into a transport medium, stored at 
−70°C, and shipped to the Marshfield Clinic Re-
search Institute (Marshfield, Wisconsin), where 
the validated eSensor RVP multiplex assay (Gen-
Mark) was used for viral diagnosis.
Details of the immunogenicity and safety 
evaluations are provided in Sections S1.5 and 
S1.6. RSV serologic tests included measurements 
of serum anti-F IgG concentrations and levels of 
antibodies competitive with palivizumab (i.e., 
antibodies that block binding of the neutralizing 
and protective monoclonal antibody palivizumab 
to RSV F protein and thus are likely to bind at or 
near the same site on the F protein). RSV A and 
B microneutralization assays have been com-
pleted in a subgroup comprising participants in 
the first two seasons of the trial to date; further 
testing is under way to examine the hypothesis 
that these assays may provide correlates of risk.7
The sponsor designed the trial and analyzed 
the data with input from the investigators; the 
investigators collected the data and conducted 
the trial. The first and last authors vouch for the 
accuracy and completeness of the data and for 
the fidelity of the trial to the protocol. The in-
vestigators worked under confidentiality agree-
ments with the sponsor.
The protocol was reviewed and approved by 
regulatory authorities in all countries and by ethi-
cal review committees at all trial sites. All the 
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maternal participants provided written informed 
consent, and parental consent for the participation 
of infants was obtained according to the standards 
at each trial site. An independent data and safety 
monitoring board monitored safety in an unblind-
ed manner throughout active enrollment.
Trial Objectives
The primary objective was to show the efficacy 
of maternal immunization with RSV F protein 
vaccine for the protection of infants against 
RSV-associated, medically significant lower re-
spiratory tract infection up to 90 days of life (the 
primary end point). RSV-associated, medically 
significant lower respiratory tract infection was 
defined as at least one manifestation of lower 
respiratory tract infection (cough, nasal flaring, 
indrawing of the lower chest wall, subcostal re-
tractions, stridor, rales, rhonchi, wheezing, crack-
les or crepitations, or observed apnea) plus hy-
poxemia (peripheral oxygen saturation of <95% 
at sea level or of <92% at an altitude of >1800 m) 
or tachypnea (≥70 breaths per minute from 0 to 
59 days of age and ≥60 breaths per minute at 
60 days of age or older); the presence of RSV in 
nasal swab samples was confirmed by the cen-
tral laboratory.
There were two secondary objectives. The 
first was to show vaccine efficacy against RSV-
associated lower respiratory tract infection with 
severe hypoxemia through 90 days of life, and 
the second was to show vaccine efficacy against 
RSV-associated lower respiratory tract infection 
with documented hospitalization through 90 days 
of life. RSV-associated lower respiratory tract 
infection was defined as at least one manifesta-
tion of lower respiratory tract infection (cough, 
nasal flaring, indrawing of the lower chest wall, 
subcostal retractions, stridor, rales, rhonchi, 
wheezing, crackles or crepitations, or observed 
apnea). Severe hypoxemia was defined as the pres-
ence of one of the following criteria: a periph-
eral oxygen saturation lower than 92% at sea 
level or lower than 87% at an altitude greater 
than 1800 m or the use of high-flow nasal can-
nula, continuous positive airway pressure, bilevel 
positive airway pressure, bubble continuous pos-
itive airway pressure, bag-mask ventilation, intu-
bation with subsequent mechanical (or manual) 
ventilation, or extracorporeal membrane oxygen-
ation. Further details of the secondary objectives 
are provided in Section S1.7.
If vaccine efficacy was shown through 90 days 
for the primary and secondary objectives, a hier-
archical sequence of hypothesis testing was to 
be carried out to examine vaccine efficacy up to 
120, 150, and 180 days of life. Details of other 
secondary analyses (e.g., safety and immunoge-
nicity), exploratory analyses (e.g., between-group 
differences in the percentages of infants with 
lower respiratory tract infection from any cause), 
Figure 1 (facing page). Screening, Enrollment,  
and Randomization.
Data regarding the disposition and demographic charac‑
teristics of the participants, safety, and immunogenicity 
were obtained from the complete and locked database 
(date of data extraction, September 27, 2019). Efficacy 
data were obtained from the locked database after all 
the participants had completed the 180‑day follow‑up 
(date of data extraction, January 30, 2019); these data 
represented the official efficacy analysis set. The safety 
population comprised all maternal participants who 
had undergone randomization and received the respira‑
tory syncytial virus fusion protein nanoparticle vaccine 
(RSV F vaccine) or placebo and their live‑born infants. 
Data on exclusions are derived from incomplete informed 
consent documentation, lost or incomplete source doc‑
umentation, or both. The intention‑to‑treat efficacy 
analysis population included all maternal participants 
and their infants in the safety analysis population for 
whom at least one respective post‑treatment or post‑
partum efficacy measurement was available for both 
the mother and the infant, as evidenced by collection  
of surveillance observations. The maternal participants 
in the per‑protocol efficacy analysis population were 
those who received the assigned RSV F vaccine or pla‑
cebo, had at least one post‑treatment encounter with 
trial personnel during which active or passive surveil‑
lance (or both) for RSV illness could have been performed, 
and had no major protocol deviations affecting the pri‑
mary efficacy end point, as determined and document‑
ed by the sponsor before database lock and unblinding. 
The infant participants in the per‑protocol efficacy pop‑
ulation were those who were born at 37 weeks or more 
of gestation, who were born to maternal participants 
who had undergone randomization and received the 
assigned vaccine or placebo at least 2 weeks before de‑
livery, and who did not receive prophylactic treatment 
with palivizumab between the day of birth and day 180 
after delivery, had at least one postpartum encounter 
with trial personnel during which active or passive sur‑
veillance (or both) for RSV illness could have been per‑
formed, and had no major protocol deviations affecting 
the primary efficacy end point, as determined and doc‑
umented by the sponsor before database lock and un‑
blinding. Participants who were excluded from one or 
more analysis populations may have had more than one 
of the listed major protocol deviations or exclusionary 
characteristics. Per‑protocol status in an infant required 
elements of per‑protocol performance in the mother.
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4636 Were enrolled and underwent randomization
5849 Pregnant women were assessed for eligibility
3051 Were assigned to receive
RSV F vaccine
1585 Were assigned to receive
placebo
2907 Completed trial through
day 180
144 Discontinued trial
54 Were lost to follow-up
48 Withdrew (unrelated 
to an adverse event)
8 Were nonadherent
5 Had adverse event
5 Were withdrawn
by investigator
1 Was withdrawn owing
to sponsor request
23 Had other reason
3014 Infants were born alive
15 Were stillbirths or fetal
losses 
2783 Infants completed trial  
through day 364
246 Discontinued trial
93 Were lost to follow-up
64 Had other reason
49 Were withdrawn 
(unrelated to
adverse event)




1510 Completed trial through
day 180
75 Discontinued trial
27 Withdrew (unrelated 
to an adverse event)




1 Was withdrawn owing
to sponsor request
15 Had other reason
1565 Infants were born alive
9 Were stillbirths or fetal
losses 
1433 Infants completed trial  
through day 364
141 Discontinued trial
58 Were lost to follow-up
34 Had other reason
25 Were withdrawn 
(unrelated to
adverse event)




1 Was withdrawn owing
to sponsor request
3008 Were included in the safety
analysis
2980 Were included in the
intention-to-treat efficacy
analysis
2765 Were included in the per-
protocol efficacy analysis




126 Did not participate
in study procedure
46 Had other reason
21 Missed visit
12 Had visit outside date
range
2 Did not have specific sur-
veillance procedures done
1 Had incomplete informed
consent
225 Were born at <37 wk of
gestation, <2 wk after
maternal dosing, or both
3045 Were included in the safety
analysis
3007 Were included in the
intention-to-treat efficacy
analysis
3004 Were included in the per-
protocol efficacy analysis




133 Did not participate  
in study procedure
36 Missed visit
10 Had visit outside date
range
7 Met exclusion criteria
3 Had incomplete informed
consent
2 Did not meet inclusion
criteria
2 Had excluded concomitant
medication or procedure
2 Had vaccination error
74 Had other reason
1561 Were included in the safety
analysis
1574 Were included in the
intention-to-treat efficacy
analysis
1430 Were included in the per-
protocol efficacy analysis




73 Did not participate
in study procedure
17 Had other reason
11 Missed visit
2 Had visit outside date
range
2 Did not have specific sur-
veillance procedures done
136 Were born at <37 wk of 
gestation, <2 wk after
maternal dosing, or both
1581 Were included in the safety
analysis
1574 Were included in the
intention-to-treat efficacy
analysis
1569 Were included in the per-
protocol efficacy analysis




69 Did not participate  
in study procedure
23 Missed visit
6 Met exclusion criteria
4 Had visit outside date
range
2 Were given incorrect
treatment
2 Had vaccination error
1 Had incomplete informed
consent
1 Had excluded concomitant
medication or procedure
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Table 1. Baseline Demographic Characteristics and Other Characteristics of the Maternal Participants and Birth and 
Household Characteristics of their Infants.*
Characteristic RSV F Vaccine Placebo
Maternal participants
Maternal participants — no.† 3045 1581
Demographic characteristics at baseline
Maternal age — yr 26±5.3 26±5.2
Race — no. (%)‡
Black 1335 (43.8)  682 (43.1)
White  903 (29.7)  489 (30.9)
Asian  320 (10.5)  168 (10.6)
Other  487 (16.0)  242 (15.3)
Hispanic or Latino ethnic group — no.(%)§  409 (13.4)  212 (13.4)
Body‑mass index¶ 28.6±5.0 28.5±5.1
Primigravida — no. (%) 1060 (34.8)  525 (33.2)
≤3 Prior pregnancies — no. (%) 2916 (95.8) 1515 (95.8)
Other characteristics




Vaginal — no./total no. (%)‖ 2201/3007 (73.2) 1132/1555 (72.8)
Cesarean — no./total no. (%)**  806/3007 (26.8)  423/1555 (27.2)
Data not available — no./total no. (%)  38/3045 (1.2)  26/1581 (1.6)
Infant participants
Infant participants — no. 3008 1561
Birth characteristics
Male sex — no. (%) 1556 (51.7)  799 (51.2)
Interval from vaccine or placebo administration to de‑
livery
Mean — days 51.9±20.4 51.3±20.7
<14 days — no. (%)  50 (1.7)  36 (2.3)
14 to <30 days — no. (%)  437 (14.5)  216 (13.8)
≥30 days — no. (%) 2521 (83.8) 1309 (83.9)
Gestational age at delivery††
Mean — wk 39.3±1.5 39.3±1.6
≥37 wk — no./total no. (%) 2811/2986 (94.1) 1458/1554 (93.8)
<37 wk — no./total no. (%) 175/2986 (5.9)  96/1554 (6.2)
Data not available — no./total no. (%)  22/3008 (0.7)   7/1561 (0.4)
Weight — kg  3.2±0.5  3.2±0.5
Length — cm 50.0±2.9 50.2±3.1
Frontal‑occipital circumference — cm 34.2±2.1 34.2±1.8
Median Apgar score (interquartile range)
At 1 min 9 (8–9)  9 (8–9)
At 5 min 10 (9–10) 9.5 (9–10)
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and post hoc analyses (e.g., comparisons between 
high-income countries and low- or middle-income 
countries, as classified according to the World 
Bank ranking,8 with respect to primary, second-
ary, and exploratory end points of lower respira-
tory tract infection) are provided in Section S1.8 
and in the protocol and statistical analysis plan.
Randomization and Conduct of the Trial
Randomization was performed centrally, with a 
separate blocking strategy for each trial site and 
with stratification according to maternal age (see 
Section S1.3). We randomly assigned women, in 
1:1 ratio in the first global RSV season and in a 
2:1 ratio thereafter, to receive vaccine (120 μg of 
RSV F vaccine adsorbed to 0.4 mg of aluminum)9 
or placebo (formulation buffer without alumi-
num). The trial was planned as a group-sequen-
tial design with up to two interim analyses. 
However, enrollment was slower than planned, 
and after 2 years, the sponsor elected to conduct 
an informational analysis (performed by the in-
dependent statistician who conducted analyses 
for the data and safety monitoring board). This 
analysis indicated that vaccine efficacy was pres-
ent at a prespecified minimum level (approxi-
mately 40%) that was deemed to be sufficient to 
warrant further investment, with no other infor-
mation provided. Enrollment was continued for 
a further season in the Northern and Southern 
Hemispheres and then terminated after enroll-
ment in the vaccine group exceeded the mini-
mum safety database target of 3000, at which 
point it was believed that a sufficient number 
of cases had been captured to test the primary 
hypothesis. End-point data that were accrued 
after the data lock for the informational analysis 
were included in the final analysis.
Statistical Analysis
We planned to enroll up to 8618 pregnant women 
on the basis of a group sequential design with 
two planned interim analyses with approximately 
4600 and 6600 enrolled participants, a projected 
percentage of infants with a primary end-point 
event of 4% and a vaccine efficacy of approxi-
mately 60%. The primary and secondary efficacy 
analyses were performed in the per-protocol 
population, which included infants who were 
born at 37 weeks or more of gestation, who were 
born to maternal participants who had under-
gone randomization and received the assigned 
vaccine or placebo at least 2 weeks before deliv-
ery, and who did not receive prophylactic treat-
ment with palivizumab between the day of birth 
and day 180 after delivery, had at least one post-
Characteristic RSV F Vaccine Placebo
Household characteristics at day 0 — no. (%)
Infants with a smoker living in the household  755 (25.1)  414 (26.5)
Infants with other children <5 yr of age living in the 
household
1161 (38.6)  618 (39.6)
Infants with other children <5 yr of age who attend group 
care ≥3 days/wk living in the household
 590 (19.6)  326 (20.9)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. RSV F vaccine denotes respi‑
ratory syncytial virus fusion protein nanoparticle vaccine.
†  Of the 4636 maternal participants enrolled, 10 (0.2%) had incomplete consent or other source documentation that 
could not be recovered (4 in the vaccine group and 6 in the placebo group). These participants and their infants were 
excluded from all analyses.
‡  Race was reported by the maternal participant of each mother–infant pair for herself and for her infant.
§  Ethnic group was reported by the maternal participant of each mother–infant pair for herself and for her infant.
¶  The body‑mass index is the weight in kilograms divided by the square of the height in meters.
‖  Vaginal deliveries included spontaneous vaginal deliveries and forceps‑ or vacuum‑assisted deliveries.
**  Cesarean deliveries included planned repeat and primary procedures, cesarean section after failed attempts at vaginal 
delivery, and emergency procedures. Emergency cesarean deliveries accounted for 6.5% of all deliveries in high‑income 
countries and for 14.5% of all deliveries in low‑ or middle‑income countries; no effect of vaccine administration was 
observed in either economic stratum.
††  Gestational age at delivery was calculated only for participants for whom the protocol‑mandated dating ultrasonogra‑
phy result was available.
Table 1. (Continued.)
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partum encounter with trial personnel during 
which active or passive surveillance (or both) for 
RSV illness could have been performed, and had 
no major protocol deviations affecting the pri-
mary efficacy end point, as determined and docu-
mented by the sponsor before database lock and 
unblinding (see Section S1.9). These efficacy 
analyses were performed with clinical data gen-
erated by trained staff at the trial sites, including 
pulse oximetry measurements obtained with the 
sponsor-provided device; RSV diagnoses were 
made at the trial central laboratory with the use 
of the molecular assay validated for the trial. 
Prespecified analyses of the primary and sec-
ondary end points, based on the same data, were 
also performed in the intention-to-treat popula-
tion, which included participants who had any 
visit during which efficacy data might have been 
gathered, regardless of treatment errors or pro-
tocol deviations.
In order to maximize illness ascertainment, 
particularly in seriously ill infants hospitalized at 
institutions unaffiliated with trial sites and thus 
not readily accessible to site staff and protocol 
pulse oximetry, we also performed exploratory 
“expanded-data” intention-to-treat analyses that 
included physical findings, pulse oximetry data, 
and RSV diagnoses extracted from the medical 
records of infants hospitalized for respiratory or 
infectious illness. Further exploratory analyses of 
lower respiratory illnesses from any cause, irre-
spective of the detection of a specific pathogen, 
in both the per-protocol and intention-to-treat 
populations also used these expanded data. All 
primary and secondary end points, as well as 
exploratory end points of RSV illnesses that met 
the primary and secondary end-point definitions 
but that were evaluated with the use of expanded 
data, were validated by an independent adjudica-
tion committee of three pediatricians before the 
data were unblinded. Estimates of vaccine effi-
cacy were calculated as percentages [(1−relative 
risk) × 100] and were based on the relative risk 
and confidence intervals obtained with the use 
of Poisson regression models with robust error 
variance.10 The reported confidence intervals for 
secondary, exploratory, and post hoc analyses 
were not adjusted for multiplicity and should be 
viewed as descriptive and not used to infer de-
finitive treatment effects for these end points. 
Vaccine efficacy against the primary end point 
(RSV-associated, medically significant lower re-
spiratory tract infection) through the first 90 
days of life was analyzed with the use of a one-
sided type I error rate of 0.0124 based on a Pocock 
spending function (i.e., lower bound of a two-
sided 97.52% confidence interval). This type I 
error rate arose from the original group-sequen-
tial design but was retained to guard against 
type I error inflation after the informational 
analysis. The Food and Drug Administration 
criterion for success with respect to the primary 
objective (i.e., to show vaccine efficacy against 
the primary end point) was a lower bound of the 
97.52% confidence interval of 30% or greater; 
the criterion of other authorities was a lower 
bound greater than 0%. All other efficacy analy-
ses used a 95% confidence interval, with a lower 
bound greater than 0% as the criterion of suc-
cess (without adjustment for multiplicity).
R esult s
Patients
Between December 3, 2015, and May 2, 2018, a 
total of 4636 women were enrolled, of whom 
3051 (65.8%) were randomly assigned to re-
ceive the RSV F vaccine (Fig. 1). Among the 
4636 women enrolled, 52.3% were enrolled in 
South Africa and 23.3% were enrolled in the 
United States (Table S1). There were 4579 live 
births. Of the 4636 women, 10 (0.2%) had in-
complete consent or other source documenta-
tion that could not be recovered (4 in the vac-
cine group and 6 in the placebo group). These 
participants and their infants were excluded 
from all analyses. A total of 4195 infants 
(91.6%) were included in the per-protocol pop-
ulation, and 4527 infants (98.9%) were includ-
ed in the intention-to-treat population (Fig. 1). 
The characteristics of the women at baseline 
and of the infants, as well as gestational age at 
the time that vaccine or placebo was adminis-
tered, were similar in the two trial groups 
(Table 1), including when stratified according 
country income level (high-income country or low- 
or middle-income country) (Tables S2 and S3).
Primary and Secondary End Points
The percentage of infants who had RSV-associ-
ated, medically significant lower respiratory tract 
infection through 90 days was 1.5% in the vac-
cine group and 2.4% in the placebo group (esti-
mated vaccine efficacy in the per-protocol analy-
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sis, 39.4%; 97.52% confidence interval [CI], −1.0 to 
63.7; 95% CI, 5.3 to 61.2) (Table 2). An analysis 
that was based on the same definition and data 
but that was performed in the intention-to-treat 
population yielded an efficacy estimate of 32.2% 
(95% CI, −4.2 to 55.9) (Table S15). The results of 
analyses that used expanded data sources in the 
intention-to-treat population are provided in 
Table 2. The results for various efficacy end 
points in infants at 120, 150, and 180 days of life 
are provided in Table S14. Kaplan–Meier survival 
curves based on analyses in the per-protocol 
population are provided in Figure 2.
The percentage of infants in the per-protocol 
population with RSV-associated lower respiratory 
tract infection with severe hypoxemia through 
90 days was 0.5% in the vaccine group and 1.0% 
in the placebo group (vaccine efficacy, 48.3%; 
95% CI, −8.2 to 75.3; vaccine efficacy in the in-
tention-to-treat population was 44.4% (95% CI, 
−14.9 to 73.1), as determined with the use of 
clinical site data only, and 58.8% (95% CI, 31.9 
to 75.0), as determined with the use of expanded 
data (Table 2 and Table S15). The percentage of 
infants in the per-protocol population who were 
hospitalized for RSV-associated lower respira-
tory tract infection through 90 days was 2.1% in 
the vaccine group and 3.7% in the placebo group 
(vaccine efficacy, 44.4%; 95% CI, 19.6 to 61.5); 
the results in the intention-to-treat population 
were closely similar to those of the per-protocol 
analysis: 48.1% (95% CI, 26.1 to 63.5), as deter-
mined with the use of clinical site data only, and 
46.4% (95% CI, 24.7 to 61.9), as determined with 
the use of expanded data (Table 2 and Table S15). 
Point estimates of vaccine efficacy through 120, 
150, and 180 days of life declined relative to the 
first 90 days of life with respect to the end point 
of RSV-associated, medically significant lower re-
spiratory tract infection, but the estimates re-
mained similar throughout with respect to the 
end points of hospitalization for RSV-associated 
lower respiratory tract infection and RSV-associ-
ated lower respiratory tract infection with severe 
hypoxemia in both the per-protocol and expanded-
data intention-to-treat analyses.
Exploratory End Points
The rate of medically significant lower respira-
tory tract infections from any cause through the 
first 90 days of life was 5.5 events per 100 in-
fants in the vaccine group and 7.2 events per 100 
in the placebo group (vaccine efficacy in the 
per-protocol analysis, 23.2%; 95% CI, 1.4 to 40.2) 
(Table 2). The corresponding rates for lower re-
spiratory tract infection from any cause with 
severe hypoxemia through 90 days of life were 
1.7 and 3.1 events per 100 infants (vaccine effi-
cacy, 46.0%; 95% CI, 18.7 to 64.1), and the rates 
for lower respiratory tract infection from any 
cause with hospitalization through 90 days of 
life were 4.3 and 6.0 events per 100 infants (vac-
cine efficacy, 27.8%; 95% CI, 4.8 to 45.3). The 
results of the expanded-data intention-to-treat 
analysis were similar to those of the per-proto-
col analysis (Table 2). The effects of vaccine on 
lower respiratory tract infection from any cause 
appeared to be durable through 180 days of life.
Estimates of vaccine efficacy against the vari-
ous end points in both per-protocol and expand-
ed-data intention-to-treat analyses, stratified ac-
cording to country income level, are provided in 
Table S16. Efficacy estimates were greater in low- 
or middle-income countries than in high-income 
countries in general, whereas the percentages of 
infants with end-point events were lower in high-
income countries and the confidence bounds for 
vaccine efficacy estimates were therefore wider. 
Estimates of vaccine efficacy against lower respi-
ratory tract infection according to RSV subtype 
(A or B) are provided in Table S17.
Estimates of vaccine efficacy against RSV-
associated lower respiratory tract infection of 
any severity and against RSV-associated, medi-
cally significant lower respiratory tract infection 
according to the definition of tachypnea used by 
the WHO (10 breaths per minute less than in the 
protocol definition) were 15 to 19% over the 
Figure 2 (facing page). Kaplan–Meier Survival Plots  
for the Primary and Secondary Efficacy End Points  
in the Per-Protocol Population.
Shown are the Kaplan–Meier survival plots for the pri‑
mary efficacy end point of RSV‑associated, medically 
significant lower respiratory tract infection (Panel A) 
and the secondary efficacy end points of RSV‑associated 
lower respiratory tract infection with severe hypoxemia 
(Panel B) and hospitalization for RSV‑associated lower 
respiratory tract infection (Panel C). For each panel, the 
main figure depicts the percentage of infants in the per‑
protocol population who survived without the occurrence 
of the specified end‑point event as a function of time 
from delivery. Because the events under study occurred 
in 5% of the infant population or less over the first 180 
days of life, insets are provided to show the same data 
on an enlarged y axis.
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first 90 days of life, declining to 12 to 13% over 
the first 180 days of life (Table S18). There was 
no clear efficacy against lower respiratory tract 
infection from any cause when events of any 
severity were included in the analysis. The inci-
dence of RSV-associated symptomatic respiratory 
tract infection was similar among the women 
who received RSV F vaccine (4.9% [148 of 3004]) 
and among those who received placebo (4.8% 
[76 of 1569]) through 180 days post partum.
Safety
Local injection-site reactions were predominantly 
mild and were more common among the women 
who received the vaccine than among those who 
received placebo (40.7% vs. 9.9%; P<0.001) (Ta-
ble 3 and Table S4). Fever within 7 days after 
vaccination occurred in 1.2% of the women who 
received the active vaccine and in 1.6% of the 
women who received placebo; the frequency of 
systemic reactions overall was similar in the two 
groups of women. No clear between-group dif-
ferences were observed with regard to the per-
centages of women who had unsolicited adverse 
events, including the prespecified adverse events 
of special interest or adverse delivery outcomes 
(Table 3 and Section S2.2.4 and Tables S5, S7, 
and S9).
The overall percentages of infants who had 
common or serious adverse events or protocol-
defined adverse events of special interest were 
also similar in each trial group (Table 3, and 
Tables S6, S8, and S10). However, serious ad-
verse events coded as “pneumonia” were less 
common among the infants in the vaccine group 
(2.2%) than among those in the placebo group 
(4.5%) through 364 days (Table 3).
Immunogenicity
Fourteen days after injection of the RSV F vac-
cine (the timing of peak levels in phase 2), the 
geometric mean concentration of palivizumab-
competitive antibodies was 12.39 times (95% CI, 
11.98 to 12.81) as high as it was before injection, 
and the geometric mean concentration of anti-F 
IgG was 18.59 times (95% CI, 17.84 to 19.36) as 
high.7,9 Additional results for these antibodies as 
well as RSV A and B microneutralization titers 
are provided in Table S11. Transient decreases in 
RSV antibody levels in women were observed at 
the time of delivery; the levels rebounded at day 
35 post partum and then declined at day 180 post 
partum.
The geometric mean concentrations of anti-F 
IgG and palivizumab-competitive antibodies in 
cord blood were 9501 ELISA (enzyme-linked im-
munosorbent assay) units (EU) per milliliter 
(95% CI, 9224 to 9787) and 136 μg per milliliter 
(95% CI, 132 to 139), respectively, among the 
infants in the vaccine group and 752 EU per milli-
liter (95% CI, 719 to 786) and 15 μg per millili-
ter (95% CI, 14 to 15), respectively, among the 
infants in the placebo group. In the vaccine 
group, the ratio of antibody concentration in 
cord blood to antibody concentration in the 
mother at the time of delivery was 1.04 (95% CI, 
1.02 to 1.06) for palivizumab-competitive anti-
bodies and 1.17 (95% CI, 1.14 to 1.19) for anti-F 
IgG. The estimated antibody half-life in the in-
fants in the vaccine group was 49.1 for palivizu-
mab-competitive antibodies and 38.3 for anti-F 
IgG. The results of analyses of transplacental 
antibody transfer overall and as stratified ac-
cording to country income level are provided in 
Tables S11 and S12.
Discussion
We report the results of a large-scale efficacy 
trial of an investigational RSV F vaccine admin-
istered during pregnancy. Vaccine efficacy against 
RSV-associated, medically significant lower re-
spiratory tract infection in the first 90 days of 
life, during which about three quarters of cases 
occurred, was 39% (97.52% CI, −1.0 to 63.7) in 
the per-protocol analysis; these results did not 
meet the prespecified criterion for success (lower 
bound of the 97.52% CI of ≥30%). Vaccine effi-
cacy in secondary analyses was 48.3% (95% CI, 
−8.2 to 75.3) against RSV-associated lower respi-
ratory tract infection with severe hypoxemia and 
44.4% (95% CI, 19.6 to 61.5) against hospitaliza-
tion for RSV-associated lower respiratory tract 
infection.
Although there were, as expected, more local 
injection-site reactions with vaccine than with 
placebo, the overall percentages of participants 
having adverse events or serious adverse events 
were similar in the two groups. The post hoc 
observation that infants born to women who 
received the RSV F vaccine were approximately 
50% less likely to have all-cause pneumonia re-
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Table 3. Safety Profile in Maternal and Infant Participants.*
Adverse Event RSV F Vaccine Placebo
Maternal participants reporting adverse events  
through the 180-day postdelivery trial visit
Maternal participants — no. 3045 1581
Any adverse event that occurred subsequent to the admin‑
istration of RSV F vaccine or placebo — no. (%)
2501 (82.1) 1204 (76.2)
Solicited adverse events — no. (%)†
Reactogenicity within 7 days after dosing 1737 (57.0) 653 (41.3)
Local injection‑site reaction 1240 (40.7) 157 (9.9)
Systemic reaction 1255 (41.2) 611 (38.6)
Fever of any severity within 7 days after dosing  37 (1.2) 25 (1.6)
Unsolicited adverse events — no. (%) 2005 (65.8) 1022 (64.6)
Severe and related adverse event‡ 2 (<0.1) 4 (0.3)
Medically attended adverse event 1534 (50.4) 802 (50.7)
Serious adverse event — no. (%)§  906 (29.8) 455 (28.8)
Protocol‑specified pregnancy and puerperium adverse 
event of special interest — no. (%)§
 377 (12.4) 190 (12.0)
Infant participants with adverse events from birth  
through the 364th-day-of-life trial visit
Infant participants — no. 3008 1561
Any adverse event — no. (%) 2477 (82.3) 1295 (83.0)
Severe and related adverse event‡ 0 0
Medically attended adverse event 2058 (68.4) 1091 (69.9)
Serious adverse event§ 1332 (44.3) 724 (46.4)
Serious adverse event with outcome of death  17 (0.6) 12 (0.8)
Protocol‑specified adverse event of special interest  
— no. (%)¶
274 (9.1) 151 (9.7)
Serious adverse event coded to the MedDRA preferred  
term “pneumonia” — no. (%)‖
 66 (2.2) 70 (4.5)
*  Data in this table represent analyses through 180 day of postpartum follow‑up for maternal participants and through 
364 days of life for infant participants; there was a 14‑day trial‑visit window for both maternal and infant participants. 
Analyses were generated from the data obtained from the locked database as of September 27, 2019, and were per‑
formed in the safety analysis population (all maternal participants who had undergone randomization and received the 
RSV F vaccine or placebo and their live‑born infants). MedDRA denotes Medical Dictionary for Regulatory Activities.
†  Solicited adverse events were common postvaccinal adverse events that were solicited by diary from day 0 through day 
6 after injection.
‡  Severe and related adverse events were those that substantially prevented the performance of normal daily activities 
and were assessed by the clinical investigators to be at least possibly related to the RSV F vaccine or placebo.
§  Serious adverse events were those that were fatal or life‑threatening, caused or prolonged hospitalization, led to persis‑
tent disability, or were congenital anomalies or birth defects. In this trial, all congenital anomalies, regardless of how 
minor, were treated as serious adverse events.
¶  Protocol‑defined adverse events of special interest were adverse events that occurred during pregnancy and the puerpe‑
rium that reflected the recommendations of the Brighton Collaboration task forces regarding safety data collection for 
maternal immunization.11.
‖  Serious adverse events coded to the MedDRA preferred term “pneumonia” showed an imbalance between the trial 
groups that suggested a relative risk of 0.49 in infants of immunized maternal participants, which was associated with 
an unadjusted P value lower than 0.001. This P value is smaller than any other in the analyses of serious adverse events 
by more than 2 orders of magnitude (Table S10). Further details on solicited adverse events are provided in Table S4; 
on unsolicited adverse events that were reported in at least 1% of maternal or infant participants in Tables S5 and S6, 
respectively; on all serious adverse events in maternal and infant participants in Tables S9 and S10, respectively; and 
all protocol‑specified adverse events of special interest in maternal and infant participants in Tables S7 and S8, respec‑
tively.
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ported as a serious adverse event through 180 or 
364 days of life is consistent with a potential 
benefit of the vaccine. Also suggestive of a pos-
sible benefit are the results with respect to the 
secondary end point of vaccine efficacy against 
RSV-associated lower respiratory tract infection 
with severe hypoxemia and the results of explor-
atory analyses of vaccine efficacy against hospi-
talization for lower respiratory tract infection 
from any cause and lower respiratory tract infec-
tion from any cause with severe hypoxemia in 
the first 90 days of life. Given their exploratory 
nature and the lack of adjustment for multiplic-
ity, these analyses, as well as the expanded-data 
intention-to-treat analyses, should be viewed as 
hypothesis-generating.
Although the trial was not powered to evaluate 
vaccine efficacy according to country (or accord-
ing to country income level), vaccine efficacy 
against RSV-associated, medically significant 
lower respiratory tract infection, RSV-associated 
lower respiratory tract infection with severe hy-
poxemia, and hospitalization for RSV-associated 
lower respiratory tract infection appeared to be 
greater in low- or middle-income countries than 
in high-income countries. However, there were 
substantially fewer cases and wide confidence 
intervals in the latter group. Further reasons 
for the apparent lower efficacy in high-income 
countries might include hospitalization for less 
severe cases, lower prevalence of breast-feeding, 
and lower background rates of severe RSV-asso-
ciated lower respiratory tract infection because 
of factors such as less exposure to indoor smoke 
or to crowding and later introduction to social 
contact.
Our trial has several limitations. The study 
was underpowered because of overestimation of 
the percentage of infants who would have a pri-
mary end-point event, for which no applicable 
antecedent data existed, and because of the 
early termination of the trial. In addition, testing 
of cord blood for RSV A and B neutralizing anti-
bodies has not yet been completed; the results of 
such testing are required to fully elucidate the 
association of RSV neutralizing antibody, anti-F 
IgG, and palivizumab-competitive antibody lev-
els with the risk of RSV-associated lower respira-
tory tract infection in infants. Further analyses 
will attempt to establish correlates of protection 
against RSV-associated lower respiratory tract 
infection, which could inform immunogenicity-
bridging studies. Additional studies are required 
to determine whether variation in vaccine effi-
cacy between high-income countries and low- or 
middle-income countries is a consistent finding, 
as well as to evaluate the effectiveness of mater-
nal RSV vaccination for the prevention of RSV-
associated lower respiratory tract infection in 
infants born preterm.
In conclusion, in this randomized, placebo-
controlled trial, maternal RSV F vaccine admin-
istered during pregnancy had an overall adverse 
event profile similar to placebo. The results with 
respect to the primary end point did not meet 
prespecified criteria for vaccine efficacy. How-
ever, the results with respect to the other end 
points of RSV-associated and all-cause respira-
tory disease in infants suggested potential ben-
efits of maternal RSV vaccination that warrant 
further study of this strategy.
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